ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FATE Fate Therapeutics Inc

3.635
-0.125 (-3.32%)
Last Updated: 17:33:07
Delayed by 15 minutes
Share Name Share Symbol Market Type
Fate Therapeutics Inc NASDAQ:FATE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.125 -3.32% 3.635 3.63 3.64 3.77 3.6125 3.70 1,106,320 17:33:07

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

25/10/2023 1:00pm

GlobeNewswire Inc.


Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more Fate Therapeutics Charts.

Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023 at 5:00 PM ET to report its third quarter 2023 financial results and provide a corporate update.

In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens, and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:Christina TartagliaStern Investor Relations, Inc.212-362-1200christina.tartaglia@sternir.com

1 Year Fate Therapeutics Chart

1 Year Fate Therapeutics Chart

1 Month Fate Therapeutics Chart

1 Month Fate Therapeutics Chart

Your Recent History

Delayed Upgrade Clock